Compare SNDL & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNDL | DMAC |
|---|---|---|
| Founded | 2006 | 2000 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 432.6M | 457.2M |
| IPO Year | 2019 | N/A |
| Metric | SNDL | DMAC |
|---|---|---|
| Price | $2.24 | $9.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $5.00 | ★ $15.50 |
| AVG Volume (30 Days) | ★ 2.8M | 581.8K |
| Earning Date | 11-04-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $683,170,243.00 | N/A |
| Revenue This Year | $5.48 | N/A |
| Revenue Next Year | $3.10 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.43 | N/A |
| 52 Week Low | $1.15 | $3.19 |
| 52 Week High | $2.89 | $10.42 |
| Indicator | SNDL | DMAC |
|---|---|---|
| Relative Strength Index (RSI) | 70.31 | 69.32 |
| Support Level | $1.66 | $7.76 |
| Resistance Level | $1.75 | $10.42 |
| Average True Range (ATR) | 0.08 | 0.71 |
| MACD | 0.06 | 0.09 |
| Stochastic Oscillator | 94.26 | 64.37 |
SNDL Inc is a private-sector liquor and cannabis retailer in Canada with retail banners that include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, and Spiritleaf. The principal activities of the company are the retailing of wines, beers, and spirits. It comprised four reportable segments: liquor retail, cannabis retail, cannabis operations, and investments. Liquor retail includes the sale of wines, beers, and spirits through owned liquor stores. The company generates maximum revenue from liquor retail.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.